Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chairman, CEO & President

CHAIRMAN, CEO & PRESIDENT

VP FINANCE AND CAO

VP Patent and General Counsel

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that is in phase Ib clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders; and OMS405 that is in phase II clinical trials for opioid and nicotine addiction. In addition, the company develops MASP-2-small-molecule inhibitors for the treatment of aHUS, HSCT-TMA, and age-related macular degeneration; GPR174 inhibitors and chimeric antigen receptor T-Cell and adoptive T-Cell therapies for various cancers; and G protein-coupled receptors for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therape...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2023-11-17	Premium	bought	Premium	Premium	Premium	Chairman, CEO & President
2023-11-15	Premium	bought	Premium	Premium	Premium	-
2023-11-14	Premium	acquired	Premium	Premium	Premium	Chairman, CEO & President
2023-11-13	Premium	acquired	Premium	Premium	Premium	Chairman, CEO & President
2023-09-12	Premium	acquired	Premium	Premium	Premium	-
2023-05-22	Premium	sold	Premium	Premium	Premium	-
2023-05-22	Premium	acquired	Premium	Premium	Premium	-
2023-05-22	Premium	sold	Premium	Premium	Premium	-
2023-05-22	Premium	acquired	Premium	Premium	Premium	-
2021-09-08	Premium	acquired	Premium	Premium	Premium	-
2021-06-17	Premium	acquired	Premium	Premium	Premium	CHAIRMAN, CEO & PRESIDENT
2021-06-17	Premium	sold	Premium	Premium	Premium	CHAIRMAN, CEO & PRESIDENT
2021-06-15	Premium	acquired	Premium	Premium	Premium	CHAIRMAN, CEO & PRESIDENT
2021-06-15	Premium	sold	Premium	Premium	Premium	CHAIRMAN, CEO & PRESIDENT
2021-05-20	Premium	sold	Premium	Premium	Premium	CHAIRMAN, CEO & PRESIDENT
2021-05-20	Premium	acquired	Premium	Premium	Premium	CHAIRMAN, CEO & PRESIDENT
2021-05-19	Premium	sold	Premium	Premium	Premium	CHAIRMAN, CEO & PRESIDENT
2021-05-19	Premium	acquired	Premium	Premium	Premium	CHAIRMAN, CEO & PRESIDENT
2021-04-08	Premium	acquired	Premium	Premium	Premium	CHAIRMAN, CEO & PRESIDENT
2021-04-08	Premium	sold	Premium	Premium	Premium	CHAIRMAN, CEO & PRESIDENT
2021-04-07	Premium	acquired	Premium	Premium	Premium	CHAIRMAN, CEO & PRESIDENT
2021-04-07	Premium	sold	Premium	Premium	Premium	CHAIRMAN, CEO & PRESIDENT
2021-02-22	Premium	acquired	Premium	Premium	Premium	-
2021-02-22	Premium	sold	Premium	Premium	Premium	VP FINANCE AND CAO
2021-02-22	Premium	acquired	Premium	Premium	Premium	VP FINANCE AND CAO

OMER - Omeros Corp Stock Price, Fair Value and News

Latest Insider Trading transactions for OMER